Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

Table 2 NF-κB staining by patient and tumor characteristics, the VUMC TROC

Characteristic	N	% *	p52 (Non-canonical NF-κB transcription factor)				p65 (Canonical NF-κB transcription factor)
			Cytoplasmic		Nuclear		Cytoplasmic		Nuclear
			Median	P-value **	Median	P-value **	Median	P-value **	Median	P-value **
Race
White	180	(91.8)	135.9	0.698	1.0	0.815	156.1	0.956	2.7	0.831
Black, other, & unknown	16	(8.2)	122.8		1.0		144.0		2.4
Stage of disease ^a
Early (I/II)	58	(29.6)	81.0	*< 0.001*	0.0	*< 0.001*	135.0	0.065	1.8	0.133
Late (III/IV)	137	(69.9)	164.8		1.8		158.6		3.0
Histologic subtype
Serous	143	(72.9)	152.0	*< 0.001*	2.2	*< 0.001*	165.4	*< 0.001*	3.9	*< 0.001*
Endometrioid & clear cell	35	(17.9)	97.7		0.0		118.8		0.4
Mucinous & others	18	(9.2)	12.1		0.0		122.8		1.4
Grade - all cases
Borderline	19	(9.7)	38.3	*< 0.001*	0.0	0.005	123.4	0.017	1.6	*0.002*
Low-grade	33	(16.8)	103.6		0.4		127.4		0.0
High-grade	144	(73.5)	157.8		1.6		160.0		3.9
Grade - invasive serous
Low-grade serous	13	(7.5)	117.2	0.057	1.0	0.237	146.0	0.027	1.4	0.034
High-grade serous	118	(67.8)	165.8		3.2		168.1		4.2
Residual disease ^b
Optimal	60	(53.1)	121.4	0.102	1.6	0.723	157.3	0.970	2.6	0.191
Suboptimal	53	(46.9)	168.7		1.7		158.6		3.8
Chemotherapy
Platinum and/or taxane	152	(77.6)	152.0	*0.002*	1.6	0.010	156.5	0.090	2.8	0.145
None or unknown	44	(22.4)	91.4		0.0		144.7		1.8
Response to platinum ^c
Platinum sensitive	105	(77.7)	152.0	0.538	1.6	0.558	161.4	0.771	2.8	0.808
Resistant or refractory	30	(22.2)	142.8		1.0		146.5		3.8

* Column percentages may not sum to 100% due to rounding error
** Bold values denote significant differences by the Kruskal-Wallis test; those in italics denote that significance surpasses a Bonferroni corrected threshold for multiple comparisons (P-value ≤ 0.003571)
^a Excluding one case with unstaged disease
^b Among cases who had debulking surgery and outcomes ascertained
^c Among patients who had dates of first-line platinum chemotherapy available

ISSN: 2050-7771